Perioperative endocrine–metabolic biomarkers for treatment stratification in glioblastoma: linking systemic dynamics to myeloid immune states
- 1Department of Neurosurgery, West China Hospital, Sichuan University
Abstract
Adult IDH-wildtype glioblastoma remains largely resistant to immunotherapy, even though selected patients develop measurable immune responses. Treatment begins within a rapidly changing perioperative endocrine and metabolic environment. Glioblastoma resection, dexamethasone, acute stress, dysglycemia, altered nutrition, infection, and tissue repair can reshape systemic metabolism and immune-cell composition within hours, while residual glioblastoma tissue undergoes spatially heterogeneous myeloid remodeling over days to weeks. This Review evaluates perioperative exposures, routine blood measures, circulating multi-omics, extracellular vesicles, paired blood-tissue analyses, and mechanistic studies of myeloid immunometabolism in adult IDH-wildtype glioblastoma. Dexamethasone exposure, glycemic status, and blood-derived inflammatory indices are clinically accessible, but most reported associations remain confounded and do not define treatment thresholds. Longitudinal lipidomic, metabolomic, proteomic, and cellular measurements can detect treatment-related state transitions; without standardized timing and tissue anchoring, however, their biological sources remain uncertain. Mechanistic studies connect glucose-lactate signaling, histone lactylation, lipid handling, hypoxia, and cell-of-origin transitions with myeloid suppression, but therapeutic evidence is still largely preclinical. We therefore propose an exposure-time-compartment-biology-decision framework for glioblastoma biomarker development. Its present role is to strengthen trial stratification, confounding control, and pharmacodynamic interpretation, not to justify unvalidated dexamethasone adjustment, immunotherapy selection, or vaccine timing at the bedside.
Related
- Fractional tumor burden refines prognostic stratification beyond MGMT status in glioblastoma after chemoradiotherapy
- Precision risk stratification for perioperative safety of minimally invasive versus open TLIF in elderly patients with lumbar degenerative disease
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
- Core needle biopsy washout biomarkers combined with ultrasound for preoperative axillary risk stratification in breast cancer: a retrospective nomogram study with temporal validation
- RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification
BibTeX
@article{zhan2026perioperative,
title = {{Perioperative endocrine–metabolic biomarkers for treatment stratification in glioblastoma: linking systemic dynamics to myeloid immune states}},
author = {Wenyi Zhan and Lirui Dai and Peizhi Zhou},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.2022519},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.2022519/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Perioperative endocrine–metabolic biomarkers for treatment stratification in glioblastoma: linking systemic dynamics to myeloid immune states
AU - Wenyi Zhan
AU - Lirui Dai
AU - Peizhi Zhou
PY - 2026
DA - 2026/11/16
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.2022519
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.2022519/full
AB - Adult IDH-wildtype glioblastoma remains largely resistant to immunotherapy, even though selected patients develop measurable immune responses. Treatment begins within a rapidly changing perioperative endocrine and metabolic environment. Glioblastoma resection, dexamethasone, acute stress, dysglycemia, altered nutrition, infection, and tissue repair can reshape systemic metabolism and immune-cell composition within hours, while residual glioblastoma tissue undergoes spatially heterogeneous myeloid remodeling over days to weeks. This Review evaluates perioperative exposures, routine blood measures, circulating multi-omics, extracellular vesicles, paired blood-tissue analyses, and mechanistic studies of myeloid immunometabolism in adult IDH-wildtype glioblastoma. Dexamethasone exposure, glycemic status, and blood-derived inflammatory indices are clinically accessible, but most reported associations remain confounded and do not define treatment thresholds. Longitudinal lipidomic, metabolomic, proteomic, and cellular measurements can detect treatment-related state transitions; without standardized timing and tissue anchoring, however, their biological sources remain uncertain. Mechanistic studies connect glucose-lactate signaling, histone lactylation, lipid handling, hypoxia, and cell-of-origin transitions with myeloid suppression, but therapeutic evidence is still largely preclinical. We therefore propose an exposure-time-compartment-biology-decision framework for glioblastoma biomarker development. Its present role is to strengthen trial stratification, confounding control, and pharmacodynamic interpretation, not to justify unvalidated dexamethasone adjustment, immunotherapy selection, or vaccine timing at the bedside.
SN - 1664-2392
ER -